Eton Pharmaceuticals Stock Soars to Record High

Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance for the year. The company sells treatments for rare diseases and pediatric endocrinology. During the June quarter, Eton Pharmaceuticals (ETON) generated $37.6 million in sales. Sales skyrocketed 99% and handily beat expectations for $27.1 million, according to FactSet.